11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)

Show full item record



Permalink

http://hdl.handle.net/10138/237632

Citation

Cancer Imaging. 2018 Aug 02;18(1):25

Title: 11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)
Author: Salminen, Antti; Jambor, Ivan; Merisaari, Harri; Ettala, Otto; Virtanen, Johanna; Koskinen, Ilmari; Veskimae, Erik; Sairanen, Jukka; Taimen, Pekka; Kemppainen, Jukka; Minn, Heikki; Boström, Peter J
Publisher: BioMed Central
Date: 2018-08-02
URI: http://hdl.handle.net/10138/237632
Abstract: Abstract Background To evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC). Methods Eighteen patients were prospectively enrolled. Fifteen treatment naive patients underwent 11C-acetate PET/MRI before transurethral resection of bladder tumor (TUR-BT) for primary tumor evaluation. Five patients with muscle invasive BC were imaged after NAC and prior to radical cystectomy (RC) with extended pelvic lymph node dissection (ePLND) for NAC treatment response evaluation. Two patients were part of both cohorts. 11C-acetate PET/MRI findings were correlated with histopathology. Accuracy for lymph node detection was evaluated on patient and the ePLND template (10 regions) levels. Results The sensitivity, specificity and accuracy of 11C-acetate PET/MRI for the detection of muscle invasive BC was 1.00, 0.69 and 0.73 while the area under the receiver operating characteristic curve (95% confidence interval) was 0.85 (0.55–1.0), respectively. All five NAC patients underwent chemotherapy as planned and 11C-acetate PET/MRI correctly staged three patients, overstaged one and understaged one patient compared with RC and ePLND findings. A total of 175 lymph node were removed, median of 35 (range, 27–43) per patient in five patients who had RC and ePLND while 12 (7%) harboured metastases. Sensitivity, specificity, accuracy and AUC for N-staging were 0.20, 0.96, 0.80 and 0.58 on the ePLND template (10 regions) level. Conclusions 11C-acetate PET/MRI is feasible for staging of BC although sensitivity for the detection of nodal metastases is low. Monitoring response to NAC shows promise and warrants evaluation in larger studies. Trial registration ClinicalTrials.gov Identifier: NCT01918592 , registered August 8 2013
Subject: Bladder cancer
11C-acetate
PET/MRI
Neoadjuvant chemotherapy
Rights: The Author(s).


Files in this item

Total number of downloads: Loading...

Files Size Format View
40644_2018_Article_158.pdf 6.471Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record